Ibandronate
- Generic Name
- Ibandronate
- Brand Names
- Bondronat, Boniva, Bonviva, Iasibon, Ibandronic acid Accord, Ibandronic Acid Sandoz, Ibandronic Acid Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C9H23NO7P2
- CAS Number
- 114084-78-5
- Unique Ingredient Identifier
- UMD7G2653W
- Background
Ibandronate, or BM 21.0955, is a third generation, nitrogen containing bisphosphonate similar to zoledronic acid, minodronic acid, and risedronic acid. It is used to prevent and treat postmenopausal osteoporosis. Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.
Ibandronate was granted FDA approval on 16 May 2003.
- Indication
For the treatment and prevention of osteoporosis in postmenopausal women.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Osteoporosis
A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- First Posted Date
- 2006-09-18
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 356
- Registration Number
- NCT00377234
Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate
- Conditions
- Osteoporosis
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 300
- Registration Number
- NCT00327990
- Locations
- 🇳🇱
GSK Investigational Site, Zaandam, Netherlands
Ibandronate or Zoledronate in Treating Patients With Newly Diagnosed Bone Metastases From Breast Cancer
- Conditions
- Breast CancerHypercalcemia of MalignancyMetastatic Cancer
- Interventions
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- Wales Cancer Trials Unit
- Target Recruit Count
- 1404
- Registration Number
- NCT00326820
- Locations
- 🇬🇧
St. Mary's Hospital, Newport, England, United Kingdom
🇬🇧Dorset Cancer Centre, Poole Dorset, England, United Kingdom
🇬🇧Alexandra Healthcare NHS, Redditch, Worcestershire, England, United Kingdom
A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 67
- Registration Number
- NCT00303485
S0308 Zoledronate or Ibandronate in Preventing Bone Problems in Women With Stage IV Breast Cancer That Has Spread to the Bone
- Conditions
- Breast CancerHypercalcemia of MalignancyMetastatic CancerPain
- Interventions
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00301886
Study in Elderly Patients With Early Breast Cancer (ICE)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- German Breast Group
- Target Recruit Count
- 1500
- Registration Number
- NCT00196859
- Locations
- 🇩🇪
Prof. Dr. med. Ulrike Nitz, Mönchengladbach, Nordrhein-Westfalen, Germany
A Study To Assess the Quality and Strength of Bone in Women Participants With Osteoporosis Taking Oral Ibandronate Versus Placebo
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 98
- Registration Number
- NCT00148915
- Locations
- 🇺🇸
GSK Investigational Site, Duncansville, Pennsylvania, United States
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
- Conditions
- Post-Menopausal Osteopenia
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 160
- Registration Number
- NCT00129623
S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 6097
- Registration Number
- NCT00127205
A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
- Conditions
- Bone NeoplasmNeoplasm MetastasisPain
- Interventions
- First Posted Date
- 2004-12-10
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT00099177
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.